stockrow
Friday 6 November 2026
Export BIO.B’s income statement to Excel — free account
Bio-Rad Laboratories, Inc.
BIO.B Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.
- Revenue
- +0.52%
- EPS
- +234.9%
- Free cash flow
- +8.07%
- Total debt
- +0.11%
Quarter to September 2026, against a year earlier
379.50
15.35
+4.22%
Follow BIO.B
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
9.57 | 35.59 | 45.54 | 11.12 |
+8 more quarters Free account |
P/S ratio |
3.77 | 3.06 | 2.90 | 3.28 | |
P/FCF ratio |
29.57 | 22.33 | 20.87 | 22.49 | |
P/Operating CF |
101.42 | 80.34 | 69.39 | 51.37 | |
P/B ratio |
1.29 | 1.11 | 1.09 | 1.14 | |
Price to Tangible BV |
1.41 | 1.23 | 1.23 | 1.26 | |
EV/Sales |
3.61 | 2.90 | 2.76 | 3.15 | |
EV/EBITDA |
0.00 | 141.53 | 123.95 | 172.31 | |
EV/Operating CF |
20.00 | 15.26 | 13.99 | 15.28 | |
EV/FCF |
28.32 | 21.16 | 19.87 | 21.59 | |
Quick Ratio |
0.44 | 2.14 | 2.17 | 3.87 | |
Current Ratio |
3.18 | 3.14 | 3.21 | 5.62 | |
Net Debt/EBITDA |
(24.23) | (5.71) | (10.60) | 2.84 | |
Debt/Assets |
11.17% | 11.74% | 12.29% | 11.37% | |
Debt/Equity |
0.16 | 0.17 | 0.18 | 0.16 | |
Asset Turnover |
0.25 | 0.25 | 0.27 | 0.26 | |
Operating CF/Net income |
0.21 | 0.27 | (0.21) | 0.23 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(4.04) | 6.00 | 2.77 | (9.83) | |
Research and Development Expense of Revenue |
0.00% | 9.40% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
39.17% | 32.57% | 35.87% | 31.88% | |
Intangible Assets out of Total Assets |
0.06 | 0.07 | 0.08 | 0.07 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
(0.01) | (0.01) | 0.00 | (0.03) | |
Graham Number |
493.72 | 224.21 | 186.92 | 414.65 | |
Earnings Yield |
10.45% | 2.81% | 2.20% | 9.00% | |
Free Cash Flow Yield |
3.38% | 4.48% | 4.79% | 4.45% | |
Revenue per Share |
24.51 | 24.34 | 21.96 | 25.43 | |
Operating CF per Share |
3.60 | 3.69 | 4.01 | 6.05 | |
Capex per Share |
0.00 | (1.20) | (1.11) | (1.68) | |
Free Cash Flow per Share |
3.60 | 2.49 | 2.90 | 4.37 | |
Cash per Share |
0.00 | 60.51 | 58.04 | 56.51 | |
Shareholders Equity per Share |
283.91 | 268.22 | 254.15 | 273.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
283.91 | 268.22 | 254.15 | 273.40 | |
Free Cash Flow |
96.40 | 66.60 | 78.20 | 119.10 | |
Working Capital |
2,109.50 | 2,059.20 | 2,025.10 | 2,389.20 | |
Capital Expenditures |
— | (32.10) | (29.90) | (45.80) | |
Net Current Asset Value |
(101.50) | (57.60) | 3.40 | (216.70) | |
EV/EBIT |
0.00 | 141.53 | 123.95 | 172.31 | |
Capex to Sales |
0.00 | 0.05 | 0.05 | 0.07 | |
Price to Operating Income |
0.00 | 149.34 | 130.23 | 179.46 | |
| Other line items | |||||
Average Receivables |
443.65 | 455.85 | 425.45 | 456.55 | |
Average Payables |
131.15 | 141.40 | 135.50 | 125.65 | |
Average Inventory |
783.55 | 789.70 | 780.30 | 750.35 | |
Average Assets |
10,239.75 | 10,233.05 | 9,658.45 | 9,970.30 | |
Average Common Equity |
7,169.90 | 7,151.30 | 6,765.35 | 7,011.45 |
Columns are period end dates · fundamentals updated 4 Nov 2026